| pubmed-article:2971827 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0019163 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0026591 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0021270 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0577559 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0205148 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C0039260 | lld:lifeskim |
| pubmed-article:2971827 | lifeskim:mentions | umls-concept:C2728259 | lld:lifeskim |
| pubmed-article:2971827 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:2971827 | pubmed:dateCreated | 1988-11-2 | lld:pubmed |
| pubmed-article:2971827 | pubmed:abstractText | To evaluate the efficacy of the mass hepatitis B vaccination program in Taiwan in interrupting perinatal hepatitis B virus transmission, 3464 randomly selected 18-month-old infant vaccinees born to hepatitis B surface antigen-carrier mothers were recruited from 9697 eligible infants during a six-month period of the program. They were divided into ten groups according to maternal infectivity and compliance with the vaccination schedule. Serum samples were tested for hepatitis B surface antigen, antibody to hepatitis B surface antigen, and antibody to hepatitis B core antigen. In 786 infants who had highly infectious mothers and who received hepatitis B immune globulin and vaccine on schedule, the protective efficacy was about 85%. The efficacy seemed to be slightly lower in those immunized off schedule. Overall, 11% of infants still carried hepatitis B surface antigen, and 81% of the infants had antibody to hepatitis B surface antigen that exceeded 10 mIU/mL in more than 90% of them. The geometric mean titers of antibody to hepatitis B surface antigen were more than 200 mIU/mL in every group of infants. We conclude that the mass vaccination program is efficacious in preventing perinatal hepatitis B virus transmission and the chronic carrier state; most infant vaccinees have adequate levels of protective antibody at 18 months of age. This program is extremely significant in the control of hepatitis B virus infection in Taiwan. | lld:pubmed |
| pubmed-article:2971827 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2971827 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2971827 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2971827 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2971827 | pubmed:issn | 0098-7484 | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:EhlMM | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:WangC YCY | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:EmptUU | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:LeeC CCC | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:ChuangC HCH | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:ChengS HSH | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:WangY FYF | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:HsuH MHM | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:ILGFF | lld:pubmed |
| pubmed-article:2971827 | pubmed:author | pubmed-author:JwoD MDM | lld:pubmed |
| pubmed-article:2971827 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2971827 | pubmed:day | 21 | lld:pubmed |
| pubmed-article:2971827 | pubmed:volume | 260 | lld:pubmed |
| pubmed-article:2971827 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2971827 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2971827 | pubmed:pagination | 2231-5 | lld:pubmed |
| pubmed-article:2971827 | pubmed:dateRevised | 2006-11-7 | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:meshHeading | pubmed-meshheading:2971827-... | lld:pubmed |
| pubmed-article:2971827 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2971827 | pubmed:articleTitle | Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. | lld:pubmed |
| pubmed-article:2971827 | pubmed:affiliation | Bureau of Disease Control, Department of Health, Taipei, Taiwan, Republic of China. | lld:pubmed |
| pubmed-article:2971827 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2971827 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2971827 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2971827 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2971827 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2971827 | lld:pubmed |
